tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kostas Biliouris, 36 are a BUY (73.47%), 13 are a HOLD (26.53%).
Analyst Kostas Biliouris, currently employed at BMO, carries an average stock price target met ratio of 28.55% that have a potential upside of 23.14% achieved within 110 days.
Kostas Biliouris’s has documented 104 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 22-Sep-2025.
Analyst best performing recommendations are on BEAM (BEAM THERAPEUTICS ).
The best stock recommendation documented was for BEAM (BEAM THERAPEUTICS ) at 7/18/2022. The price target of $61 was fulfilled within 1 day with a profit of $2.99 (5.15%) receiving and performance score of 51.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$21
$-4.75 (-18.45%)
$25
2 months 1 days ago
(05-Aug-2025)
11/11 (100%)
$2.7 (14.75%)
145
Buy
$55
$29.25 (113.59%)
$78
5 months ago
(06-May-2025)
0/4 (0%)
$38.77 (238.88%)
Buy
$70
$44.25 (171.84%)
$105
5 months ago
(06-May-2025)
0/3 (0%)
$53.77 (331.30%)
$40
$14.25 (55.34%)
$57
5 months 14 days ago
(22-Apr-2025)
2/5 (40%)
$20.13 (101.31%)
4
Buy
$80
6 months ago
(06-Apr-2025)
0/7 (0%)
$54.31 (211.41%)
Which stock is Kostas Biliouris is most bullish on?
Which stock is Kostas Biliouris is most reserved on?
What Year was the first public recommendation made by Kostas Biliouris?
